{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:19:35Z","timestamp":1770355175969,"version":"3.49.0"},"publisher-location":"New York, NY","reference-count":55,"publisher":"Springer US","isbn-type":[{"value":"9781071631744","type":"print"},{"value":"9781071631751","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3175-1_12","type":"book-chapter","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:13Z","timestamp":1684479733000},"page":"211-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Activated Protein C Resistance Using Thrombin Generation Test"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5298","authenticated-orcid":false,"given":"Jonathan","family":"Douxfils","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Morimont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"issue":"Suppl 1","key":"12_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/10245330512331390195","volume":"10","author":"B Dahlback","year":"2005","unstructured":"Dahlback B (2005) The importance of the protein C system in the pathogenesis of venous thrombosis. Hematology 10(Suppl 1):138\u2013139. https:\/\/doi.org\/10.1080\/10245330512331390195","journal-title":"Hematology"},{"issue":"15","key":"12_CR2","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1016\/j.febslet.2005.03.001","volume":"579","author":"B Dahlback","year":"2005","unstructured":"Dahlback B, Villoutreix BO (2005) The anticoagulant protein C pathway. FEBS Lett 579(15):3310\u20133316. https:\/\/doi.org\/10.1016\/j.febslet.2005.03.001","journal-title":"FEBS Lett"},{"key":"12_CR3","doi-asserted-by":"publisher","unstructured":"Morimont L, Donis N, Bouvy C, Mullier F, Dogne JM, Douxfils J (2022) Laboratory testing for the evaluation of phenotypic activated protein C resistance. Semin Thromb Hemost 48(6):680\u2013689. https:\/\/doi.org\/10.1055\/s-0042-1753511","DOI":"10.1055\/s-0042-1753511"},{"issue":"3 Suppl","key":"12_CR4","doi-asserted-by":"publisher","first-page":"26S","DOI":"10.1378\/chest.124.3_suppl.26s","volume":"124","author":"CT Esmon","year":"2003","unstructured":"Esmon CT (2003) The protein C pathway. Chest 124(3 Suppl):26S\u201332S. https:\/\/doi.org\/10.1378\/chest.124.3_suppl.26s","journal-title":"Chest"},{"issue":"3","key":"12_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","volume":"122","author":"G Tans","year":"2003","unstructured":"Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR (2003) Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 122(3):465\u2013470. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04443.x","journal-title":"Br J Haematol"},{"issue":"11","key":"12_CR6","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1182\/blood-2003-10-3578","volume":"103","author":"E Castoldi","year":"2004","unstructured":"Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J (2004) Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 103(11):4173\u20134179. https:\/\/doi.org\/10.1182\/blood-2003-10-3578","journal-title":"Blood"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","volume":"130","author":"F Rodeghiero","year":"1999","unstructured":"Rodeghiero F, Tosetto A (1999) Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 130:643\u2013650","journal-title":"Ann Intern Med"},{"issue":"4","key":"12_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","volume":"93","author":"MCH de Visser","year":"1999","unstructured":"de Visser MCH, Rosendaal FR, Bertina RM (1999) A reduced sensitivity for activated protein C in the absence of factor V leiden increases the risk of venous thrombosis. Blood 93(4):1271\u20131276. https:\/\/doi.org\/10.1182\/blood.V93.4.1271","journal-title":"Blood"},{"issue":"1","key":"12_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000315141","volume":"37","author":"TJ Cramer","year":"2010","unstructured":"Cramer TJ, Griffin JH, Gale AJ (2010) Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb 37(1):17\u201323. https:\/\/doi.org\/10.1159\/000315141","journal-title":"Pathophysiol Haemost Thromb"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/joim.1997.242.s740.1","volume":"740","author":"B Dahlbck","year":"1997","unstructured":"Dahlbck B (1997) Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis. J Intern Med Suppl 740:1\u20138","journal-title":"J Intern Med Suppl"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1477-9560-4-15","volume":"4","author":"S Khan","year":"2006","unstructured":"Khan S, Dickerman JD (2006) Hereditary thrombophilia. Thromb J 4:15. https:\/\/doi.org\/10.1186\/1477-9560-4-15","journal-title":"Thromb J"},{"issue":"1","key":"12_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","volume":"13","author":"JL Kujovich","year":"2011","unstructured":"Kujovich JL (2011) Factor V Leiden thrombophilia. Genet Med 13(1):1\u201316. https:\/\/doi.org\/10.1097\/GIM.0b013e3181faa0f2","journal-title":"Genet Med"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/5584_2016_120","volume":"906","author":"C Hotoleanu","year":"2017","unstructured":"Hotoleanu C (2017) Genetic risk factors in venous thromboembolism. Adv Exp Med Biol 906:253\u2013272. https:\/\/doi.org\/10.1007\/5584_2016_120","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"12_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cll.2009.03.002","volume":"29","author":"B Khor","year":"2009","unstructured":"Khor B, Van Cott EM (2009) Laboratory evaluation of hypercoagulability. Clin Lab Med 29(2):339\u2013366. https:\/\/doi.org\/10.1016\/j.cll.2009.03.002","journal-title":"Clin Lab Med"},{"issue":"4","key":"12_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ajhg.2015.01.019","volume":"96","author":"M Germain","year":"2015","unstructured":"Germain M, Chasman DI, de Haan H, Tang W, Lindstrom S, Weng LC, de Andrade M, de Visser MC, Wiggins KL, Suchon P, Saut N, Smadja DM, Le Gal G, van Hylckama VA, Di Narzo A, Hao K, Nelson CP, Rocanin-Arjo A, Folkersen L, Monajemi R, Rose LM, Brody JA, Slagboom E, Aissi D, Gagnon F, Deleuze JF, Deloukas P, Tzourio C, Dartigues JF, Berr C, Taylor KD, Civelek M, Eriksson P, Cardiogenics C, Psaty BM, Houwing-Duitermaat J, Goodall AH, Cambien F, Kraft P, Amouyel P, Samani NJ, Basu S, Ridker PM, Rosendaal FR, Kabrhel C, Folsom AR, Heit J, Reitsma PH, Tregouet DA, Smith NL, Morange PE (2015) Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet 96(4):532\u2013542. https:\/\/doi.org\/10.1016\/j.ajhg.2015.01.019","journal-title":"Am J Hum Genet"},{"issue":"7","key":"12_CR16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/jth.13339","volume":"14","author":"B Pezeshkpoor","year":"2016","unstructured":"Pezeshkpoor B, Castoldi E, Mahler A, Hanel D, Muller J, Hamedani NS, Biswas A, Oldenburg J, Pavlova A (2016) Identification and functional characterization of a novel F5 mutation (Ala512Val, FVBonn) associated with activated protein C resistance. JTH 14(7):1353\u20131363. https:\/\/doi.org\/10.1111\/jth.13339","journal-title":"JTH"},{"issue":"7","key":"12_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/jth.13357","volume":"14","author":"F Bernardi","year":"2016","unstructured":"Bernardi F (2016) Better or worse than the original. Journal of thrombosis and haemostasis: JTH 14(7):1350\u20131352. https:\/\/doi.org\/10.1111\/jth.13357","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"2","key":"12_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/blood-2002-02-0343","volume":"100","author":"E Norstrom","year":"2002","unstructured":"Norstrom E, Thorelli E, Dahlback B (2002) Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 100(2):524\u2013530. https:\/\/doi.org\/10.1182\/blood-2002-02-0343","journal-title":"Blood"},{"issue":"5","key":"12_CR19","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/jth.15274","volume":"19","author":"E Castoldi","year":"2021","unstructured":"Castoldi E, Hezard N, Mourey G, Wichapong K, Poggi M, Ibrahim-Kosta M, Thomassen M, Fournel A, Hayward CPM, Alessi MC, Hackeng TM, Rosing J, Morange PE (2021) Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besancon). J Thromb Haemost 19(5):1186\u20131199. https:\/\/doi.org\/10.1111\/jth.15274","journal-title":"J Thromb Haemost"},{"issue":"1","key":"12_CR20","first-page":"21","volume":"28","author":"B Dahlback","year":"2004","unstructured":"Dahlback B (2004) APC resistance: what have we learned since 1993? J Lab Med 28(1):21\u201327","journal-title":"J Lab Med"},{"issue":"9","key":"12_CR21","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1182\/blood-2003-06-2092","volume":"103","author":"M Steen","year":"2004","unstructured":"Steen M, Norstrom EA, Tholander AL, Bolton-Maggs PH, Mumford A, McVey JH, Tuddenham EG, Dahlback B (2004) Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood 103(9):3381\u20133387. https:\/\/doi.org\/10.1182\/blood-2003-06-2092","journal-title":"Blood"},{"issue":"15","key":"12_CR22","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2013-10-530089","volume":"123","author":"K Nogami","year":"2014","unstructured":"Nogami K, Shinozawa K, Ogiwara K, Matsumoto T, Amano K, Fukutake K, Shima M (2014) Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Blood 123(15):2420\u20132428. https:\/\/doi.org\/10.1182\/blood-2013-10-530089","journal-title":"Blood"},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood.V90.4.1552","volume":"90","author":"F Bernardi","year":"1997","unstructured":"Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM (1997) A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 90:1552\u20131557","journal-title":"Blood"},{"issue":"4","key":"12_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1055\/s-0037-1613866","volume":"83","author":"MC de Visser","year":"2000","unstructured":"de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM (2000) The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 83(4):577\u2013582","journal-title":"Thromb Haemost"},{"issue":"6","key":"12_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2143\/AC.70.6.3120184","volume":"70","author":"A Aleksova","year":"2015","unstructured":"Aleksova A, Di Nucci M, Gobbo M, Bevilacqua E, Pradella P, Salam K, Barbati G, De Luca A, Mascaretti L, Sinagra G (2015) Factor-V HR2 haplotype and thromboembolic disease. Acta Cardiol 70(6):707\u2013711. https:\/\/doi.org\/10.2143\/AC.70.6.3120184","journal-title":"Acta Cardiol"},{"issue":"6","key":"12_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/j.1365-2516.2008.01775.x","volume":"14","author":"MK ten Kate","year":"2008","unstructured":"ten Kate MK, van der Meer J (2008) Protein S deficiency: a clinical perspective. Haemophilia 14(6):1222\u20131228. https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01775.x","journal-title":"Haemophilia"},{"issue":"10","key":"12_CR27","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1111\/jth.13071","volume":"13","author":"ES Yap","year":"2015","unstructured":"Yap ES, Timp JF, Flinterman LE, van Hylckama VA, Rosendaal FR, Cannegieter SC, Lijfering WM (2015) Elevated levels of factor VIII and subsequent risk of all-cause mortality: results from the MEGA follow-up study. J Thromb Haemost 13(10):1833\u20131842. https:\/\/doi.org\/10.1111\/jth.13071","journal-title":"J Thromb Haemost"},{"issue":"6","key":"12_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","volume":"157","author":"PV Jenkins","year":"2012","unstructured":"Jenkins PV, Rawley O, Smith OP, O'Donnell JS (2012) Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 157(6):653\u2013663. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09134.x","journal-title":"Br J Haematol"},{"key":"12_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010813.pub2","volume":"3","author":"M de Bastos","year":"2014","unstructured":"de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama VA, Helmerhorst FM, Stijnen T, Dekkers OM (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 3:CD010813. https:\/\/doi.org\/10.1002\/14651858.CD010813.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"12_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","volume":"94","author":"J Dinger","year":"2016","unstructured":"Dinger J, Do Minh T, Heinemann K (2016) Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 94(4):328\u2013339. https:\/\/doi.org\/10.1016\/j.contraception.2016.06.010","journal-title":"Contraception"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","volume":"143","author":"JA Heit","year":"2005","unstructured":"Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-years-based study. Ann Intern Med 143:697\u2013706","journal-title":"Ann Intern Med"},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","volume":"346","author":"H Jick","year":"1995","unstructured":"Jick H, Jick S, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589\u20131593","journal-title":"Lancet"},{"issue":"2","key":"12_CR33","doi-asserted-by":"publisher","first-page":"b2890","DOI":"10.1136\/bmj.b2890","volume":"339","author":"O Lidegaard","year":"2009","unstructured":"Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339(2):b2890. https:\/\/doi.org\/10.1136\/bmj.b2890","journal-title":"BMJ"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","volume":"312","author":"WO Spitzer","year":"1996","unstructured":"Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, Macrae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 312:83","journal-title":"BMJ"},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"b2921","DOI":"10.1136\/bmj.b2921","volume":"339","author":"VA van Hylckama","year":"2009","unstructured":"van Hylckama VA, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR (2009) The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339:b2921. https:\/\/doi.org\/10.1136\/bmj.b2921","journal-title":"BMJ"},{"key":"12_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","volume":"168","author":"D Rovinski","year":"2018","unstructured":"Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM (2018) Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res 168:83\u201395. https:\/\/doi.org\/10.1016\/j.thromres.2018.06.014","journal-title":"Thromb Res"},{"issue":"8","key":"12_CR37","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1055\/s-0040-1714140","volume":"46","author":"J Douxfils","year":"2020","unstructured":"Douxfils J, Morimont L, Bouvy C (2020) Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk. Semin Thromb Hemost 46(8):872\u2013886. https:\/\/doi.org\/10.1055\/s-0040-1714140","journal-title":"Semin Thromb Hemost"},{"issue":"5\u20136","key":"12_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.thromres.2004.08.004","volume":"114","author":"B Brenner","year":"2004","unstructured":"Brenner B (2004) Haemostatic changes in pregnancy. Thromb Res 114(5\u20136):409\u2013414. https:\/\/doi.org\/10.1016\/j.thromres.2004.08.004","journal-title":"Thromb Res"},{"key":"12_CR39","doi-asserted-by":"publisher","unstructured":"Morimont L, Haguet H, Dogn\u00e9 J-M, Gaspard U, Douxfils J (2021) Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol:12. https:\/\/doi.org\/10.3389\/fendo.2021.769187","DOI":"10.3389\/fendo.2021.769187"},{"key":"12_CR40","doi-asserted-by":"crossref","unstructured":"Douxfils J, Gaspard U, Taziaux M, Jost M, Bouvy C, Lobo RA, Utian WH, Foidart JM (2022) Impact of estetrol (E4) on hemostasis, metabolism, and bone turnover in postmenopausal women. Climacteric","DOI":"10.1080\/13697137.2022.2139599"},{"key":"12_CR41","doi-asserted-by":"publisher","unstructured":"Douxfils J, Morimont L, Gaspard U, Utian WH, Foidart JM (2022) Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation. Thromb Res. https:\/\/doi.org\/10.1016\/j.thromres.2022.09.007","DOI":"10.1016\/j.thromres.2022.09.007"},{"key":"12_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/clinem\/dgac511","volume":"108","author":"L Morimont","year":"2022","unstructured":"Morimont L, Jost M, Gaspard U, Foidart JM, Dogn\u00e9 JM, Douxfils J (2022) Low thrombin generation in users of a contraceptive containing estetrol and drospirenone. J Clin Endocrinol Metabol 108:135. https:\/\/doi.org\/10.1210\/clinem\/dgac511","journal-title":"J Clin Endocrinol Metabol"},{"key":"12_CR43","unstructured":"European Medicines Agency (2005) Guideline on clinical investigation of steroid contraceptives in women \u2013 EMEA\/CPMP\/EWP\/519\/98 Rev 1. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-investigation-steroid-contraceptives-women_en.pdf"},{"issue":"7","key":"12_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12612","volume":"5","author":"L Morimont","year":"2021","unstructured":"Morimont L, Didembourg M, Haguet H, Modaffari E, Tillier M, Bouvy C, Lebreton A, Dogne JM, Douxfils J (2021) Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay. Res Pract Thromb Haemost 5(7):e12612. https:\/\/doi.org\/10.1002\/rth2.12612","journal-title":"Res Pract Thromb Haemost"},{"key":"12_CR45","volume-title":"Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline \u2014 fifth edition","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute (2008) Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline \u2014 fifth edition. CLSI document H21-A5, Wayne"},{"issue":"2","key":"12_CR46","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1515\/cclm-2019-0471","volume":"58","author":"J Douxfils","year":"2020","unstructured":"Douxfils J, Morimont L, Delvigne AS, Devel P, Masereel B, Haguet H, Bouvy C, Dogne JM (2020) Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. CCLM\/FESCC 58(2):294\u2013305. https:\/\/doi.org\/10.1515\/cclm-2019-0471","journal-title":"CCLM\/FESCC"},{"issue":"3","key":"12_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12684","volume":"6","author":"L Morimont","year":"2022","unstructured":"Morimont L, Leclercq C, Didembourg M, De Gottal E, Carlo A, Gaspard U, Dogne JM, Douxfils J (2022) Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system. Res Pract Thromb Haemost 6(3):e12684. https:\/\/doi.org\/10.1002\/rth2.12684","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"12_CR48","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/jth.14470","volume":"17","author":"J Douxfils","year":"2019","unstructured":"Douxfils J, Morimont L, Bouvy C, de Saint-Hubert M, Devalet B, Devroye C, Dincq AS, Dogne JM, Guldenpfennig M, Baudar J, Larock AS, Lessire S, Mullier F (2019) Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. JTH 17(8):1273\u20131287. https:\/\/doi.org\/10.1111\/jth.14470","journal-title":"JTH"},{"key":"12_CR49","volume-title":"User evaluation of between-reagent lot variation","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute (2013) User evaluation of between-reagent lot variation. CLSI document EP26-A. Clinical and Laboratory Standards Institute, Wayne, PA"},{"key":"12_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.thromres.2020.08.006","volume":"193","author":"L Morimont","year":"2020","unstructured":"Morimont L, Dogne JM, Douxfils J (2020) Letter to the editors-in-chief in response to the article of Abou-Ismail, et al. entitled \u201cestrogen and thrombosis: a bench to bedside review\u201d (thrombosis research 192 (2020) 40\u201351). Thromb Res 193:221\u2013223. https:\/\/doi.org\/10.1016\/j.thromres.2020.08.006","journal-title":"Thromb Res"},{"issue":"5","key":"12_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13625187.2022.2093850","volume":"27","author":"K Gemzell-Danielsson","year":"2022","unstructured":"Gemzell-Danielsson K, Cagnacci A, Chabbert-Buffet N, Douxfils J, Foidart JM, Kubba A, Lete Lasa LI, Mansour D, Neulen J, Neves J, Palma F, Romer T, Spaczynski R, Toth V (2022) A novel estetrol-containing combined oral contraceptive: European expert panel review. Eur J Contracept Reprod Health Care 27(5):1\u201311. https:\/\/doi.org\/10.1080\/13625187.2022.2093850","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"12_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jth.14745","volume":"18","author":"L Morimont","year":"2020","unstructured":"Morimont L, Bouvy C, Delvigne AS, Dogne JM, Douxfils J (2020) Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance. JTH 18(4):895\u2013904. https:\/\/doi.org\/10.1111\/jth.14745","journal-title":"JTH"},{"issue":"6","key":"12_CR53","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","volume":"102","author":"J Douxfils","year":"2020","unstructured":"Douxfils J, Klipping C, Duijkers I, Kinet V, Mawet M, Maillard C, Jost M, Rosing J, Foidart JM (2020) Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception 102(6):396\u2013402. https:\/\/doi.org\/10.1016\/j.contraception.2020.08.015","journal-title":"Contraception"},{"key":"12_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.maturitas.2021.08.013","volume":"152","author":"J Douxfils","year":"2021","unstructured":"Douxfils J, Lobo R, Taziaux M, Jost M, Bouvy C, Gaspard U, Foidart J-M (2021) Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC). Maturitas 152:69. https:\/\/doi.org\/10.1016\/j.maturitas.2021.08.013","journal-title":"Maturitas"},{"key":"12_CR55","doi-asserted-by":"publisher","first-page":"769187","DOI":"10.3389\/fendo.2021.769187","volume":"12","author":"L Morimont","year":"2021","unstructured":"Morimont L, Haguet H, Dogne JM, Gaspard U, Douxfils J (2021) Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne) 12:769187. https:\/\/doi.org\/10.3389\/fendo.2021.769187","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Methods in Molecular Biology","Hemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3175-1_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:05:12Z","timestamp":1684479912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3175-1_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631744","9781071631751"],"references-count":55,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_12","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"20 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}